PEAK6 Investments’s bluebird bio BLUE Stock Holding History

PEAK6 Investments’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-500	Closed	-$56.6K	–	5010
2022 Q2	$41K	Buy	+500	New	+$38.8K	﹤0.01%	5573
2021 Q3	–	Sell	-1,724	Closed	-$714K	–	5177
2021 Q2	$714K	Buy	1,724 +399	+30%	+$158K	﹤0.01%	2909
2021 Q1	$518K	Buy	+1,325	New	+$652K	﹤0.01%	3165
2020 Q4	–	Sell	-440	Closed	-$279K	–	4582
2020 Q3	$307K	Sell	440 -618	-58%	-$482K	﹤0.01%	3210
2020 Q2	$836K	Sell	1,058 -3,100	-75%	-$2.34M	﹤0.01%	2254
2020 Q1	$2.48M	Buy	4,158 +2,403	+137%	+$2.34M	0.01%	890
2019 Q4	$2M	Buy	+1,755	New	+$1.91M	0.01%	1094
2019 Q3	–	Sell	-541	Closed	-$826K	–	3750
2019 Q2	$891K	Buy	541 +309	+133%	+$535K	0.01%	1856
2019 Q1	$473K	Sell	232 -157	-40%	-$276K	﹤0.01%	2418
2018 Q4	$500K	Buy	+389	New	+$597K	﹤0.01%	2336

Other funds holding BLUE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PEAK6 Investments's BLUE Position: Q3 2022 in Review

PEAK6 Investments sold out of bluebird bio (BLUE) in Q3 2022, closing a stake of 500 shares — an estimated $56.6K sold.

PEAK6 Investments first reported a position in BLUE in Q4 2018 and held it in 10 quarters. The position peaked at $2.48M in Q1 2020. 162 funds tracked by Wall St. Rank hold BLUE as of Q3 2022.

PEAK6 Investments reported no remaining bluebird bio position as of Q3 2022 after selling out during the quarter.
PEAK6 Investments sold 500 bluebird bio shares in Q3 2022, an estimated $56.6K.
PEAK6 Investments first reported a position in bluebird bio in Q4 2018 and held it in 10 quarters.
PEAK6 Investments's bluebird bio position peaked at $2.48M in Q1 2020.
162 funds tracked by Wall St. Rank held bluebird bio as of Q3 2022.

Based on PEAK6 Investments's 13F filing for Q3 2022, filed 14 Nov 2022.